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Two major types of cleavage sites with different se-
quence preferences have been proposed for the human
immunodeficiency virus type 1 (HIV-1) proteinase. To
understand the nature of these sequence preferences
better, single and multiple amino acid substitutions
were introduced into a type 1 cleavage site peptide, thus
changing it to a naturally occurring type 2 cleavage site
sequence. Our results indicated that the previous clas-
sification of the retroviral cleavage sites may not be
generally valid and that the preference for a residue at
a particular position in the substrate depends strongly
on the neighboring residues, including both those at the
same side and at the opposite side of the peptide back-
bone of the substrate. Based on these results, pseudo-
symmetric (palindromic) substrates were designed. The
retroviral proteinases are symmetrical dimers of two
identical subunits; however, the residues of naturally
occurring cleavage sites do not show symmetrical ar-
rangements, and no obvious symmetrical substrate pref-
erence has been observed for the specificity of HIV pro-
teinase. To examine the role of the asymmetry created
by the peptide bonds on the specificity of the respective
primed and nonprimed halves of the binding site, amino
acid substitutions were introduced into a palindromic
sequence. In general, the results suggested that the
asymmetry does not result in substantial differences in
specificity of the S3 and S3* subsites, whereas its effect is
more pronounced for the S2 and S2* subsites. Although it
was possible to design several good palindromic sub-
strates, asymmetrical arrangements may be preferred
by the HIV proteinase.
The specificity of retroviral proteinases has been studied
intensively using both polyproteins and oligopeptides as sub-
strates (for review, see Refs. 1–3). These studies have provided
a basis for the rational design of potent, selective inhibitors.
Various proteinase inhibitors are now in clinical trials or ap-
proved for therapy (for review, see Refs. 4–6). Comparison of
cleavage site sequences of human immunodeficiency virus type
1 (HIV-1)1 and type 2 (HIV-2) suggested that the enzyme had a
broad specificity and lacked consensus substrate sequence (7).
Initially three types of cleavage sites were proposed for HIV-1,
HIV-2, and simian immunodeficiency virus (8). Subsequently,
two major types of cleavage sites were proposed for retroviral
proteinases, type 1 having -Tyr(Phe)*Pro- and type 2 having
hydrophobic residues (excluding Pro) at the site of cleavage
(9–11). These two types of cleavage sites were proposed to have
different preferences for the P2 and P29 positions, where the
peptide bond between P1 and P19 is cleaved (notation is accord-
ing to Ref. 12). Our studies with type 1 substrates indicated a
preference for small residues like Cys or Asn at the P2 position
and a preference for b-branched Val or Ile at the P29 position
(10). The lower catalytic constants with P2 b-branched residues
were predicted to be due to steric collision with P19 Pro (10). On
the other hand, using a series of peptides based on a type 2
cleavage site, b-branched residues, especially Val, were found
to be favorable at P2, whereas Glu was preferred at P29 (11).
Interestingly, Griffith et al. (11) found Glu as the preferred P29
residue in a peptide series, when the P2-P19 sequence of a type
1 cleavage site (-Asn-Tyr*Pro-) was substituted into a type 2
substrate. Although some of the differences of the subsite spec-
ificity in type 1 and type 2 cleavage sites were explained by
molecular modeling, most of the dependence of the specificity of
proteinases on the sequence context is unexplored.
The HIV-1 proteinase is a dimer of two identical subunits. It
exhibits an exact crystallographic, 2-fold rotational (C2) sym-
metry in the structure without inhibitor (for review, see Ref. 4).
Based on this symmetry, the potential advantages of C2 sym-
metric HIV-1 proteinase inhibitors including high selectivity,
potency, and stability were proposed, and structurally symmet-
ric HIV-1 proteinase inhibitors were designed containing two
amino-terminal halves of a putative substrate (13). Crystal
structures of HIV-1 proteinase with inhibitors can be either
symmetric or asymmetric (4). The symmetry or asymmetry was
initially thought to arise from the symmetry or asymmetry of
the inhibitor, but even crystal structures of HIV proteinase
with symmetric inhibitors can have asymmetric proteinase
subunits (14).
Considering the symmetry of the HIV proteinase, a symmet-
rical preference for substrate residues would be expected for
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naturally occurring cleavage sites, since the high mutation rate
could readily evolve such sequences. However, there is no ob-
vious preference for symmetrical sequences in HIV proteinase
cleavage sites (listed in Ref. 15) or in other retroviral protein-
ase cleavage sites (see Ref. 1). Using a series of oligopeptides
containing single amino acid substitutions in a naturally oc-
curring type 1 cleavage site peptide, the respective P and P9
positions (for example, P2 and P29) appeared to be similar, but
substantial differences were also found. For example, the pep-
tide containing P2 Asn was a very good substrate; however, Asn
at P29 resulted in a poor substrate (10). It was not clear whether
these differences were because of the asymmetrical interac-
tions of the peptide amides and carbonyl oxygens in the sub-
strate or intramolecular interactions of the substrate side
chains (10).
To explore further the dependence of HIV proteinase speci-
ficity on the sequence context of its substrates we introduced
single or multiple substitutions into a type 1 cleavage site
peptide and changed it to a naturally occurring type 2 cleavage
site sequence. Based on the results obtained, we designed a
pseudosymmetric (palindromic) substrate and introduced
amino acid substitutions into this sequence to explore the effect
of asymmetry created by the peptide backbone on the different
specificities of the respective primed and nonprimed proteinase
subsites. To study whether the enzyme prefers pseudosymmet-
ric (palindromic) or asymmetric arrangements of the substrate
residues, we have also studied the doubly substituted (also
palindromic) versions of the starting pseudosymmetric
substrate.
MATERIALS AND METHODS
Oligopeptide Synthesis and Characterization—Oligopeptides were
synthesized by standard tert-butoxycarbonyl or 9-fluorenylmethyloxy-
carbonyl chemistry on a model 430A automated peptide synthesizer
(Applied Biosystems, Inc.) or a semiautomatic Vega peptide synthesizer
(Vega-Fox Biochemicals). All peptides were synthesized with an amide
end. Amino acid composition of the peptides was determined with either
a Durrum D-500 or a Waters Pico-Tag amino acid analyzer. Stock
solutions and dilutions were made in distilled water (or in 10 mM
dithiothreitol for peptides containing Cys residues), and the peptide
concentrations were determined by amino acid analysis.
Enzyme Assay—Purified HIV-1 proteinase was prepared as de-
scribed previously (16). Active site titration for the HIV-1 proteinase
was performed with compound 3 (17). The proteinase assays were
performed in 0.25 M potassium phosphate buffer, pH 5.6, containing
7.5% glycerol, 1 mM EDTA, 2.5 mM dithiothreitol, 0.1% Nonidet P-40, 2
M NaCl in the presence of 8–140 nM enzyme. The reaction mixture was
incubated at 37 °C for 1 h, and the reaction was stopped by the addition
of guanidine HCl (6 M final concentration). The solution was acidified by
the addition of trifluoroacetic acid, and an aliquot was injected onto a
Nova-Pak C18 reversed-phase chromatography column (3.9 3 150 mm,
Waters Associates, Inc.) using an automatic injector. Substrates and
the cleavage products were separated using an increasing water-aceto-
nitrile gradient (0–100%) in the presence of 0.05% trifluoroacetic acid.
Cleavage products of proteinase-catalyzed hydrolysis for these peptides
were identified by amino acid analysis and/or by NH2-terminal sequenc-
ing. Kinetic parameters were determined by fitting the data obtained at
less than 20% substrate hydrolysis to the Michaelis-Menten equation
by using the Fig. P program (Fig. P Software Corp.). The substrate
concentration was 0.01–5.0 mM depending on the approximate Km
values.
Molecular Modeling and Energy Minimization—The structures were
examined on Silicon Graphics computers running the program Sybyl
(Tripos Inc., St. Louis, MO) or CHAIN (18). The starting model for the
HIV-1 proteinase with the substrate Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-
Gln (asterisk indicates the site of cleavage) was described previously
(19). All the other enzyme-substrate structures were built from this
model by altering the side chain(s) of the appropriate residue(s). Each of
the side chain torsion angles for substituted residues in the peptide
substrate was rotated through 360° in steps of 15° to find the confor-
mation with the smallest nonbonded energy as described (20).
Energy minimization and molecular dynamics of the modified sub-
strates were run using the program AMMP (21), as described previously
(19). Finally, the model structures were examined in the computer
graphics system.
RESULTS AND DISCUSSION
Substitution of Amino Acids of a Type 1 Cleavage Site
Peptide with Residues of a Type 2 Substrate
Previously, we performed extensive comparisons of the speci-
ficities of HIV-1 and HIV-2 proteinases using oligopeptides
representing naturally occurring cleavage sites in their Gag
and Gag-Pol polyproteins (15). These cleavage sites have been
classified as type 1, which contains an aromatic amino acid and
Pro at P1 and P19, respectively, and type 2, which has mainly
hydrophobic residues but not Pro at the site of cleavage. We
showed that an oligopeptide (peptide 1 in Table I) representing
the cleavage site in p66 of HIV-1 for generating the p51 subunit
of the heterodimeric reverse transcriptase of HIV-1 and an-
other peptide (peptide 2 in Table I) representing the homolo-
gous sequence in p68 of HIV-2, and therefore proposed to be the
cleavage site (22), were substrates of the HIV proteinases (15).
These peptides, which match type 2 cleavage site sequences,
were the starting points for our design of palindromic sub-
strates since they are partly symmetric with aromatic amino
acids at the P1, P19, and they contain negatively charged resi-
dues at the P3 and P39 positions. In addition, peptide 2 also
contains Thr at both P2 and P29 positions. Furthermore, pep-
tides 1 and 2 with the exception of the P29 residues share the
same sequence in the P4-P39 region, which is the major deter-
minant for specificity (23). However, peptide 2 was found to be
a much poorer substrate of the HIV proteinases than peptide 1
(see Table I and Ref. 15).
Subsequently Fan et al. (24) demonstrated that in fact the
sequence of peptide 2 does not represent the actual cleavage
site required to be cleaved to produce the smaller subunit of the
HIV-2 reverse transcriptase. They found that the real cleavage
site has the sequence of AFAM*ALTD and is downstream from
the one proposed by Le Grice et al. (22). Nevertheless, we in
this study and Fan et al. (24) have confirmed our initial finding
that the HIV-2-derived peptide 2 or its shorter octapeptide
homolog is a substrate of the HIV-1 proteinase.
We have also compared the specificity of the HIV-1 and
HIV-2 proteinases using a series of oligopeptide substrates
containing single amino acid substitutions in the sequence of
SP-211 (see peptide 3 in Table I), a peptide that corresponds to
the type 1 MA/CA cleavage site in HIV-1 (10, 23). In these
studies it was found that substitution of Pro at the P19 position
to any other amino acid tested, including Tyr, formed nonhy-
drolyzable or very poor substrates of HIV proteinases. These
P19-substituted peptides inhibited the hydrolysis of SP-211 by
HIV proteinase, which suggested that they were able to bind to
the enzyme (10). The best inhibition was obtained with the P19
Tyr-substituted peptide,2 suggesting its high affinity for the
HIV-1 proteinase. In good agreement with these preliminary
findings, both the Km and kcat values determined in the present
study were substantially lower for the P19 Tyr-substituted pep-
tide compared with the unmodified one (compare peptides 3
and 4 in Table I). Substitution of P19 Pro of SP-211 with Tyr
converts a type 1 substrate to a type 2 substrate. However, the
P19 Tyr-substituted peptide is a poor substrate of HIV-1 pro-
teinase (peptide 4 in Table I). To understand better the speci-
ficity of HIV-1 proteinase and the differences of the subsite
preference in type 1 and type 2 cleavage sites, further single
and multiple substitutions were carried out in the type 1
MA/CA cleavage site substrate (peptide 3), introducing resi-
dues characteristic of the type 2 cleavage site peptides 1 and 2
2 J. To¨zse´r and S. Oroszlan, unpublished results.
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(Table I). The same substitutions were also introduced in the
P19 Tyr-modified (type 2) substrate. This peptide series allowed
us to compare the preference for P2 Asn over Thr as well as P29
Ile over Thr in different sequence contexts. The ln (kcat/Km)
values are directly related to the free energy of the binding of
the transition state by the enzyme (25). If the subsite interac-
tions are mostly independent of each other, the kcat/Km ratios
(equal to e2DDG/RT) for substrate pairs having X and Y residues
at the same subsite, should be similar and independent of the
surrounding sequence, as has been found for e.g. trypsin (26)
and chymotrypsin (27).
Single substitutions of P2 Asn and P29 Ile with Thr (peptides
5 and 6 in Table I, respectively) resulted in substantial in-
creases in Km and decreases in catalytic constants compared
with the unmodified peptide 3. Comparison of kinetic parame-
ters of peptides 1 and 2 as well as of peptides 3 and 6 suggests
that b-branched hydrophobic residues such as Val or Ile at P29
positions are much more favorable than the b-branched but
more hydrophilic Thr in these two different sequence contexts.
Furthermore, a similar preference was found in two other
series of peptides (11). Single substitutions of P3 Gln and P39
Val to Asp (peptide 7 and 8 of Table I, respectively) resulted in
dramatic increases in Km values but only moderate decreases
in kcat values, as was found previously for cleavage with HIV-2
proteinase (10).
Substituting Thr at P2 residue for Asn in the P19 Tyr analog
of SP-211 (peptide 9 in Table I) did not yield substantial
changes in the kinetic parameters, whereas substitution of P29
Thr for Ile in the same sequence context (peptide 10) yielded an
approximately 10-fold increase in (kcat/Km). The same substi-
tution was very unfavorable in the P19 Pro-containing peptides
(compare peptides 3 and 6 in Table I), suggesting a strong
influence of the P19 residue on the preference for the P29 resi-
due. Substitution of Thr at both the P2 and P29 positions of
peptide 4 was less effective than the single P29 substitution
(compare peptides 10 and 11 of Table I). Interestingly, whereas
the P39 Asp substitution of peptide 4 yielded a substrate that
was even less susceptible to hydrolysis (peptide 12 in Table I),
a further substitution for P2 Thr (peptide 13) yielded a sub-
strate with Km and kcat/Km values better than those of the
naturally occurring type 2 cleavage site peptide 1. As expected
from the comparison of peptides 1 and 2, further substitution of
P29 Ile for Thr yielded a substrate with much lower kcat/Km
value because of the substantial increase of the Km (peptide 14
of Table I).
Enzyme-substrate models were built and energy minimized
to explore the possible interactions of the enzyme and the
substrates at the molecular level. The substrate lies in an
extended b-conformation in the substrate binding site, which
puts P4, P2, P19, and P39 residues at one side and P3, P1, and P29
on the other side (Fig. 1). Adjacent substrate binding sites (like
S2 and S19) partially overlap (Fig. 1). Molecular modeling sug-
gested that the P2 Thr-substituted SP-211 analog could not fit
well in the S2 subsite (not shown) because of the predicted
interaction with P19 Pro, as described previously for another
b-branched amino acid, Val (10). When the P19 Pro is changed
to Tyr, this restraint is removed. However, comparison of pep-
tides 4 and 9 suggested that this substitution alone is not
sufficient to make Thr preferable over Asn in the SP-211 se-
quence context, but the additional P39 Val to Asp exchange is
required (peptides 12 and 13). However, a further substitution
of P29 Ile to Thr again resulted in Asn over Thr preference at P2
(peptides 14 and 15, see Table II).
It is of interest to note that substitution of P19 Pro to Tyr in
various sequence contexts yielded much lower Km and kcat
values (e.g. compare peptides 3 and 4, 5 and 9 etc.). Both the
substrate backbone and the proteinase residues of the S19 (and
S1) subsites may move to accommodate the large Tyr at P19
(and P1) by moving toward the overlapping and adjacent sub-
sites S2-S39 (S3-S29) and therefore restrict the space available
for other subsites (see Fig. 1). Similar movements of a mutated
residue in the substrate binding site have been observed in the
crystal structure of an inhibitor-resistant proteinase (28). The
restriction of the available space at the neighboring subsites
could be a major determinant in the sequence context-depend-
ent preference for P2 and P29. In the -P2-Tyr*Tyr-P29-Asp- con-
text there is a preference for one larger and one smaller residue
at P2 and P29 suggesting complementarity of these sites. In the
case of Ile at P29, the smaller Thr is preferred over Asn at P2
(peptides 12/13 in Table II), whereas in case of Thr at P29 the
larger Asn is preferred over Thr at P2 (peptides 14/15 in Table
II). Conversely, with the larger Asn at P2 the smaller Thr is
preferred at P29 (peptides 12/14), whereas with the smaller Thr
at P2 the larger Ile is preferred at P29 (peptides 13/15). In the
case of the -P2-Tyr*Tyr-P29-Val- context the preference is less
distinct. In accordance with the suggested P2-P29 complemen-
tarity, with P29 Thr there is a preference for the larger Asn at
P2 (peptides 10/11 in Table II), whereas with Asn at P2 there is
a preference for the smaller Thr at P29 (peptides 4/10 in Table
II). However, when P2 is Thr, P29 Thr was preferred over Ile
(peptides 9/11 in Table II). Apparently the hydrophobic,
b-branched Val at P39 may restrict the type of amino acid which
can be accommodated optimally in the S29 subsite.
In summary, results on the preference of Asn over Thr at P2
and Ile over Thr at P29 positions (Table II) suggest a very strong
dependence on sequence context. For example, P29 preference
depends not only on the P19, but also on the P2 and P39 residues.
Strop et al. (29) suggested a context dependence in the P2-P29
residues in the specificity of avian myeloblastosis virus protein-
TABLE I
Assay of substrates having the sequence of naturally occurring
cleavage sites and those containing single or multiple substitutions in
the cleavage site sequence between the matrix and capsid proteins of
HIV-1 by HIV-1 proteinase
Number Sequencea Km kcat kcat/Km
mM s21 mM21 s21
1 AETF*YVDGAAb 0.046 6 0.006 0.42 6 0.02 9.1
2 GAETF*YTDGSc 0.33 6 0.06 0.21 6 0.03 0.64
3 VSQNY*PIVQd 0.15 6 0.03 6.8 6 0.07 45.3
4 VSQNY*YIVQ 0.020 6 0.003 0.010 6 0.001 0.50
5 VSQTY*PIVQ 0.41 6 0.05 0.70 6 0.02 1.7
6 VSQNY*PTVQ 0.85 6 0.20 2.07 6 0.37 2.43
7 VSDNY*PIVQ 1.77 6 0.32 2.62 6 0.15 1.48
8 VSQNY*PIDQ 6.84 6 0.98 3.09 6 0.31 0.45
9 VSQTY*YIVQ 0.035 6 0.005 0.020 6 0.001 0.57
10 VSQNY*YTVQ 0.026 6 0.007 0.18 6 0.01 6.92
11 VSQTY*YTVQ 0.021 6 0.003 0.050 6 0.001 2.38
12 VSQNY*YIDQ ,0.02 NDe 0.09f
13 VSQTY*YIDQ 0.006 6 0.001 0.10 6 0.01 16.67
14 VSQNY*YTDQ 0.20 6 0.03 0.20 6 0.02 1.00
15 VSQTY*YTDQ 0.17 6 0.03 0.10 6 0.01 0.59
16 VSDTY*YTDQ 0.19 6 0.03 0.030 6 0.003 0.16
a Amino acids substituted in the sequence of peptide 3 are underlined.
b Peptide representing the determined cleavage site in reverse tran-
scriptase of HIV-1. Kinetic parameters for this peptide were also re-
ported in Ref. 15.
c Peptide representing a proposed cleavage site in reverse tran-
scriptase of HIV-2 (22).
d Peptide representing the MA/CA cleavage site of HIV-1 (peptide 3,
previously designated as SP-211). Kinetic parameters for this peptide
were also reported in Ref. 15.
e ND, not determined.
f Determined as competitive substrate with peptide 45 (Table V).
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ase, which was also demonstrated by Ridky et al. (30). Our
results indicate that P39, and likely other outer distal residues
like P4 and P3, may also substantially influence the preference
for a subsite. The change of preference at the P29 position as a
function of P19 and P39 residues (Table II) also suggests that the
context dependence of the specificity of HIV-1 proteinase is not
restricted only to residues located at the same side of the
peptide backbone. Molecular modeling and inspection of the
crystal structure of HIV proteinase-inhibitor complexes sug-
gest that the peptide backbone of the substrate does not occupy
a rigid position, and depending on the substitutions, it could
move toward the S or S9 sites. SP-211 contains the relatively
small Pro at P19, which may allow a relatively larger S29 sub-
site, and this peptide showed Ile over Thr preference (peptide
3/6 in Table II). A large hydrophobic residue at P19, such as Tyr,
could force the peptide backbone toward the S29 site, making it
smaller. This could be the reason for the Thr over Ile preference
at P29 in the case of the P19 Tyr-substituted peptides (see
peptides 4/10 in Table II).
Substitutions in a Palindromic Substrate Sequence
S3 and S39 Substitutions—Peptide 16 (Table I) contains a
palindromic sequence at the P3-P39 positions.
Elimination of P5 Val and substitution of P49 Gln for Ser
resulted in a completely palindromic substrate (peptide 17 in
Table III). It is important to note that this shorter peptide
showed 10-fold higher kcat and kcat/Km values than peptide 16.
The effect of residues P5 and P4 on substrate hydrolysis has
been reported previously (11, 23). To compare the specificity of
the S3 and S39 substrate binding pockets in an identical se-
quence context, the Asp residues of the palindromic peptide 17
were substituted to Gly, Gln, Phe and Leu residues (Table III).
Although the Gly and Gln residues were also doubly substi-
tuted, kinetic measurements were not possible for the doubly
substituted Phe and Leu peptides because of low solubility
(peptides 26 and 29 in Table III). Substitution of the P3 and P39
Asp to Gly (peptides 18 and 19, respectively) resulted in similar
Km and kcat values and only a 2-fold decrease in kcat/Km values.
Interestingly, changing both P3 and P39 Asp residues to Gly
yielded a much higher Km value (peptide 20). Single substitu-
tions to Gln also resulted in moderate changes in the kinetic
parameters, whereas the double substitution yielded a sub-
stantial reduction of the kcat value. Whereas substitution to P3
Phe resulted in a 4-fold decrease in Km and kcat (peptide 24),
the P39 Phe substitution did not cause such a big effect (peptide
25). Substitution of P3 or P39 Asp to Leu resulted in a substan-
tial decrease in catalytic constants.
FIG. 1. Panel A, schematic representa-
tion of the P19 Tyr-substituted HIV-1
MA/CA substrate (peptide 4 in Table I) in
the S3-S39 subsites of proteinase. The rel-
ative size of each subsite is indicated ap-
proximately by the area enclosed by the
curved line around each substrate side
chain. Panel B, stereoview of residues P3-
P39 of peptides 1 (thin lines) and 4 (thick
lines).
TABLE II





P2 P1 P19 P29 P39
3/5 Asn/Thr Tyr Pro Ile Val 26.6
4/9 Asn/Thr Tyr Tyr Ile Val 0.9
10/11 Asn/Thr Tyr Tyr Thr Val 2.9
12/13 Asn/Thr Tyr Tyr Ile Asp 0.005
14/15 Asn/Thr Tyr Tyr Thr Asp 1.7
3/6 Asn Tyr Pro Ile/Thr Val 18.6
4/10 Asn Tyr Tyr Ile/Thr Val 0.07
9/11 Thr Tyr Tyr Ile/Thr Val 0.24
12/14 Asn Tyr Tyr Ile/Thr Asp 0.09
13/15 Thr Tyr Tyr Ile/Thr Asp 28.25
a Only P2-P39 segment of the substrates are shown; the outer residues
were identical. The preferred residue is underlined.
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Modeling showed that the same residues of the enzyme in-
teract with the appropriate subsite at both sides of the scissile
bond (Table IV). S3 and S39 subsites are near the surface, and
they are formed by hydrophobic residues and two charged
residues (Table IV). In the starting palindromic substrate (pep-
tide 17) the P3 and P39 Asp residues can interact with Arg-89
and Arg-8, respectively (Fig. 2) and compensate for the lower
van der Waals energy compared with Phe in P3 and P39 posi-
tions. Surprisingly, the catalytic constants of the Gly-substi-
tuted peptides are comparable to those obtained with Phe and
Asp substitutions. Apparently, P3 and P39 in this sequence
context do not have a substantial effect on the efficiency of
hydrolysis. The largest differences between the P3 and P39
mutated peptides were obtained with Leu substitutions. Also,
these peptides had the lowest kcat/Km values. Previously, we
had proposed that the interaction between the hydrophobic P39
residue of SP-211 (see peptide 3 in Table I) and Phe-53 of the
enzyme may play a crucial role in proper closing of the flexible
flap (10). In a molecular dynamics simulation of the flap move-
ment, Phe-53 and its symmetry counterpart were among the
few residues suggested to be involved in the “triggering” event
(31). In the palindromic sequence context, although peptides
with hydrophobic residues at P39 have lower Km values than
those with polar residues or Gly (Table III), the differences are
not as dramatic as in the case of SP-211, where at least 10-fold
differences were found (peptides 3 and 8 in Table I; Ref. 10). In
our palindromic sequence context, the effect of a hydrophobic
residue at P39 resembles that of P3 in SP-211 in which only a
moderate increase of Km was obtained by introducing nonhy-
drophobic residues at P3 (10). A P19 Tyr residue in the pseudo-
symmetric context may partially occupy the overlapping S39
pocket as P1 Tyr can partially occupy the S3 (Fig. 3), resulting
in less dependence on P39 hydrophobicity for the proper closing
of the flap.
Only moderate differences were found in the kinetic param-
eters of substrates having identical substitutions at the P3 and
P39 sites, except for the Leu substitutions. These results sug-
gest that the asymmetry of the peptide backbone does not play
a major role in the large differences of the specificities of the
respective S3 and S39 subsites we had previously established
(10). Instead, the specificity differences are a consequence of
the different sequence context of the substrates.
S2 and S2 Substitutions—The P2 or P29 Thr residues of
peptide 17 (Tables III and V) were substituted with Gly, Glu,
Cys, Ala, Ile, and Leu residues (Table V). Because of the low
solubility, the doubly substituted Ile and Leu substrates were
not assayed (peptides 44 and 47, respectively). Single substi-
tutions of the Thr residues with Gly resulted in substantial
increases in Km values and decreases of kcat and kcat/Km values
compared with peptide 17, whereas the doubly substituted
peptide was not hydrolyzed (peptides 31–33 in Table V). Pre-
vious studies showed that Gly in these positions does not form
good substrates, independently of the sequence context (10, 32).
Substitution of P2 Thr to Glu resulted in a large increase in Km
value; however, this peptide showed the highest kcat value
among all of the substituted peptides (peptide 33 in Table V).
P29 Glu substitution (peptide 34) resulted in a less dramatic
increase in Km and unchanged kcat values. P29 Glu was found to
be optimal in both type 1 and type 2 sequence context by
Griffith et al. (11). This preference was predicted to be because
of hydrogen bonding of the side chain carboxyl to the backbone
NH of residues 299 and 309 of the enzyme (11). Also, P29 Glu is
frequently found in viral and cellular protein cleavage sites of
HIV-1 proteinase (33). At the P2-P29 region the type 1 substrate
used by Griffith et al. (11) contained residues (-Asn-Tyr*Pro-
Ile-) identical to those in SP-211; however, P29 Glu substitution
FIG. 2. Stereoview of residues P3-P3* of the palindromic peptide 17 (Table V). Hydrogen bond interactions between P3 Asp and Arg-89 as
well as P39 Asp and Arg-8 in the enzyme-substrate complex are shown by dashed lines.
TABLE III
Assay of P3 and P39 substituted peptides based on a palindromic
sequence by HIV-1 proteinase
Number Sequencea Km kcat kcat/Km
mM s21 mM21 s21
17 SDTY*YTDS 0.21 6 0.04 0.34 6 0.02 1.62
18 SGTY*YTDS 0.50 6 0.06 0.46 6 0.02 0.92
19 SDTY*YTGS 0.35 6 0.03 0.29 6 0.01 0.83
20 SGTY*YTGS 2.88 6 0.44 0.62 6 0.04 0.22
21 SQTY*YTDS 0.62 6 0.09 0.43 6 0.04 0.69
22 SDTY*YTQS 0.36 6 0.06 0.21 6 0.02 0.58
23 SQTY*YTQS 0.22 6 0.03 0.060 6 0.003 0.27
24 SFTY*YTDS 0.052 6 0.017 0.08 6 0.01 1.54
25 SDTY*YTFS 0.24 6 0.05 0.22 6 0.02 0.92
26 SFTY*YTFS Not determinedb
27 SLTY*YTDS 0.250 6 0.065 0.010 6 0.002 0.04
28 SDTY*YTLS 0.082 6 0.015 0.014 6 0.001 0.17
29 SLTY*YTLS Not determinedb
a Amino acids substituted in sequence 17 are underlined.
b Low solubility of the substrate did not allow the kinetic measure-
ments.
TABLE IV
Residues forming the subsites of HIV-1 proteinase
Residues interacting with the modeled peptide 17 (Table V) are listed.
Amino acid residues in the second subunit of the dimer are indicated by
a prime.
Subsite HIV-1 proteinase residues
S3 Arg-89, Leu-239, Asp-29, Gly-48, Gly-49, Phe-53, Pro-819,
Val-829
S2 Ala-28, Asp-29, Asp-30, Val-32, Ile-47, Gly-48, Gly-49,
Ile-509, Leu-76, Ile-84
S1 Arg-89, Leu-239, Asp-259, Asp-25, Gly-27, Gly-48, Gly-49,
Ile-50, Thr-809, Pro-819, Val-829, Ile-849
S19 Arg-8, Leu-23, Asp-25, Asp-259, Gly-279, Gly-489, Gly-499,
Ile-509, Thr-80, Pro-81, Val-82, Ile-84
S29 Ala-289, Asp-299, Asp-309, Val-329, Ile-479, Gly-489, Gly-499,
Ile-50, Leu-769, Ile-849
S39 Arg-8, Leu-23, Asp-299, Gly-489, Gly-499, Phe-539, Pro-81,
Val-82
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was an unfavorable substitution in the SP-211,2 suggesting the
importance of residues outside the P2-P29 determining P29 pref-
erence, as we have also found with the multisubstituted pep-
tides (Table II). Therefore, preference for Glu at P29 position of
type 1 and type 2 cleavage sites is also strongly dependent on
the surrounding substrate residues. Single substitutions of the
palindromic peptide 17 with small hydrophobic residues such
as Cys (peptides 36–37) and Ala (peptides 39–40) at P2 and P29
resulted in somewhat better Km and kcat values, as well as
higher kcat/Km values. It is interesting to note that the double
Cys substitution (peptide 38) resulted in a substantially higher
Km value and a less efficient substrate than the single substi-
tuted ones. Also, the double Ala substitution (peptide 41) did
not improve the substrate over the P2 Ala-substituted one,
although P29 Ala was also favorable over Thr in single substi-
tution. These findings suggest that symmetrical (palindromic)
arrangements do not necessarily give better substrates than
asymmetrical arrangements. The substitutions with Ile gave
lower Km and increased catalytic constants (peptides 42–43).
Only P29 Leu was a preferable substitution, whereas P2 Leu
substitution was not (peptides 45 and 46, respectively).
The S2 and S29 subsites of HIV-1 proteinase are also hydro-
phobic, but they are smaller than the S3 and S39 sites. The P2
side chain is surrounded by the hydrophobic Val-32, Ile-47,
Ile-50, Leu-76, and Ile-84 residues. The same amino acid resi-
dues of the other subunit form the S29. Comparing the kinetic
parameters of the P2 and P29 substituted substrates, the small
hydrophobic Ala was a better substitution at P2 than at P29,
whereas the larger Cys, Ile, and Leu residues were more pre-
ferred at P29, suggesting that the S29 subsite may be somewhat
larger than the S2. Interestingly, the largest differences in
kcat/Km values were found between peptides having Leu sub-
stitutions in P2 and P29 (compare peptides 45 and 46 in Table V)
as well as P3 and P39 (compare peptides 27 and 28 of Table III).
Because of the asymmetry of the peptide bonds, the pseudo-
symmetry center of the substrates is shifted approximately by
0.5 Å, positioning the carbonyl oxygen rather than the center of
the scissile bond into the line of the C2 symmetry axis of the
proteinase dimer. This deviation puts the P29 residue farther
from the center of the enzyme compared with P2 (Fig. 4),
toward the open end of the binding site, which may be a reason
why larger residues are better at P29 than at P2. The effect of
this deviation is stronger close to the center, which may be the
reason for larger differences obtained for the P2 and P29 sub-
stitutions than for the P3 and P39 substitutions. Furthermore,
whereas S3, S39 subsites are exposed at the surface, the S2, S29
subsites are more restricted because they are smaller and
inside the proteinase.
Hydrolysis of Substrates Having Palindromic Sequences
The hydrolysis of peptide 17 and its doubly substituted de-
rivatives in Tables III and V showed that peptides with com-
pletely palindromic sequences could be substrates of HIV-1
proteinase. Based on mirroring the NH2-terminal side of the
sequence of the naturally occurring MA/CA (VSQNY*PIVQ)
and CA/NC cleavage site (TATIM*MQRGN), we synthesized
other palindromic peptides, and these were also found to be
substrates of the enzyme (peptides 48 and 49 of Table VI).
Simultaneous substitution of P2 and P29 residues of peptide 49
to Ala (peptide 50) produced little change in kcat/Km. Since Tyr
is better in P1 than Met in both type 1 (10) and type 2 cleavage
site sequences (2), Tyr was substituted for Met at both P1 and
P19, which resulted in the most efficient palindromic substrate
in our series (peptide 51). These results suggests that various
palindromic substrates could be designed for HIV-1 proteinase,
FIG. 3. Stereoview of residues P1-P3* of the substituted derivatives of peptide 17 (Table V containing Gly at P3* (peptide 19 of Table
V, thick lines) and Phe at P3* (peptide 25 of Table V, thin lines).
TABLE V
Assay of P2 and P29 substituted peptides based on a palindromic
sequence by HIV-1 proteinase
Number Sequencea Km kcat kcat/Km
mM s21 mM21 s21
17 SDTY*YTDS 0.21 6 0.04 0.34 6 0.02 1.62
30 SDGY*YTDS 1.41 6 0.28 0.06 6 0.01 0.04
31 SDTY*YGDS 1.82 6 0.28 0.09 6 0.01 0.05
32 SDGY*YGDS Not hydrolyzedb
33 SDEY*YTDS 4.86 6 1.04 3.66 6 0.53 0.75
34 SDTY*YEDS 0.91 6 0.16 0.34 6 0.04 0.36
35 SDEY*YEDS 5.14 6 0.86 0.79 6 0.09 0.15
36 SDCY*YTDS 0.09 6 0.006 0.44 6 0.01 4.89
37 SDTY*YCDS 0.12 6 0.02 1.04 6 0.06 8.67
38 SDCY*YCDS 1.00 6 0.20 2.78 6 0.20 2.78
39 SDAY*YTDS 0.098 6 0.004 1.30 6 0.02 13.27
40 SDTY*YADS 0.17 6 0.04 0.82 6 0.03 4.82
41 SDAY*YADS 0.24 6 0.03 3.16 6 0.17 13.17
42 SDIY*YTDS 0.10 6 0.02 1.02 6 0.08 10.20
43 SDTY*YIDS 0.03 6 0.001 0.55 6 0.03 18.33
44 SDIY*YIDS Not determinedc
45 SDLY*YTDS 0.51 6 0.05 0.48 6 0.03 0.94
46 SDTY*YLDS 0.06 6 0.02 0.57 6 0.09 9.50
47 SDLY*YLDS Not determinedc
a Amino acids substituted in sequence 17 are underlined.
b Not hydrolyzed when incubated with 140 nM HIV-1 proteinase for
1 h at 37 °C.
c Low solubility of the substrate did not allow the kinetic measure-
ments.
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and specificity studies using these substrates could eliminate
the differences caused by the sequence context on the prefer-
ence of the respective S and S9 sites.
It is also of interest to note that exchange of P1 and P19
residues of SP-211 as well as mirroring the P9 residues resulted
in nonhydrolyzable peptides (peptides 52 and 53 of Table VI).
These results also indicate the nonequivalent nature of the
respective S and S9 subsites.
CONCLUSIONS
The dependence of the specificity of HIV-1 proteinase on the
sequence context of its substrate peptides was studied by mak-
ing single and multiple substitutions of amino acids in natu-
rally occurring cleavage site peptides, and palindromic sub-
strates were designed. Although it was possible to design
palindromic substrates, our results suggest that a symmetric
arrangement of residues may not be favorable. The S3-S39 re-
gion of the HIV proteinase is generally hydrophobic. However,
a completely hydrophobic sequence may not provide soluble
oligopeptides. Furthermore, the naturally occurring cleavage
sites in retroviruses are expected to be in regions connecting
folded protein domains of polyproteins, where a high degree of
hydrophobicity may be unfavorable for the correct conforma-
tion. Besides the hydrophobicity, the size of residues also ap-
pears to be important. Our results suggest that in the case of
tight packing of S1 and S19 with Tyr residues, a relatively
larger residue at either P2 or P29 is preferable, but not at both
positions. These factors may explain why symmetric subsite
arrangements have not evolved at the naturally occurring
cleavage sites, despite the symmetric nature of the retroviral
proteinases.
Previous studies did not explain whether the rather large
differences in specificity of respective S and S9 subsites are
attributed to the asymmetry introduced by the binding of the
substrate and/or the different amino acid sequence context.
Design of a palindromic substrate and substitutions in its re-
spective positions allowed us to study these effects. In general,
our results suggest that the previously established differences
in specificity of P3 and P39 positions could be mainly due to the
different sequence context: in these positions the asymmetry
introduced by the peptide backbone of the substrate does not
seem to play an important role. For P2 and P29 positions the
effect of asymmetry is not negligible; however, the different
sequence context could be still the predominant cause of the
substantial differences found previously (10).
Our results also show that the earlier classification of retro-
viral cleavage sites into two types is an oversimplification.
Preference of Asn in P2 and Ile in P29 in type 1 cleavage sites as
well as Ile (Val) in P2 and Glu at P29 in type 2 cleavage site
substrates seems to be a function of the residues outside of the
P2-P29 region of the substrate. The enzyme-substrate interac-
tion of the HIV-1 proteinase as well as other retroviral protein-
ases cannot be described residue by residue, but the neighbor-
ing residues of the substrate should also be taken into account.
These neighboring residues include not only the residues at the
same side of the peptide backbone but also residues at the
opposite side as suggested by Strop et al. (29) from analysis of
avian myeloblastosis virus proteinase specificity. Similar re-
sults were obtained by Ridky et al. (30) from kinetic analysis of
substrates containing double substitutions from P3 to P19 in the
NC/proteinase cleavage site peptide of Rous sarcoma virus.
However, the specificity pattern is even more complex than was
originally thought, not only the internal P2-P29 residues, but
outer residues like P39 may also substantially influence the
preference for a subsite, even for positions separated by four
residues in the peptide sequence.
The most important features of the sequence context depend-
ence are the size and b-branch in a residue. P19 Tyr, unlike Pro,
may fill completely the large S19 subsite and could restrict the
space for substrate residues at other subsites. On the other
hand, substitution of Pro at P19 could eliminate unfavorable
interactions with b-branched residues at P2 (10, 30). Even
small changes in the substrate sequence might cause rear-
rangement of the substrate residues, as seen in some enzyme-
inhibitor complexes as well as predicted by molecular model-
ing. This strong sequence context dependence also raises
difficulties for predicting cleavage sites. For example, an early
prediction method developed by Poorman et al. (7) failed to
predict the cleavage site in Nef protein (34). New prediction
methods that take into account the context-dependent nature
FIG. 4. Comparison of the interac-
tions of P2 Leu-S2 and P2* Leu-S2* of
the substituted palindromic pep-
tides. Stereoview of the P2 Leu residue of
peptide 45 (Table VI) with the residues of
S2 (shown in thin lines) rotated 180° and
superimposed on P29 Leu residue of pep-
tide 46 (Table VI) with the residues of S29
(shown in thick lines).
TABLE VI
Assay of peptides containing palindromic or inverted sequences based
on the cleavage sites between MA and CA as well as between p1 and
NC proteins of HIV as substrates of HIV-1 proteinase
Number Sequence Km kcat kcat/Km
mM s21 mM21 s21
48 VSQNY*YNQSV 0.013 6 0.003 0.05 6 0.01 3.85
49 KATIM*MITAK ,0.05a NDb 1.00c
50 KATAM*MATAK 0.34 6 0.03 0.14 6 0.01 0.41
51 KATIY*YITAK ,0.05a NDb 27.6d
52 VSQNP*YIVQ Not hydrolyzede
53 QVIP*YNQSV Not hydrolyzede
a Increasing substrate concentration above 0.05 mM resulted in a
decrease of velocity.
b ND, not determined.
c kcat/Km value was determined as competitive substrate with peptide
17 of Table III.
d kcat/Km value was determined as competitive substrate with peptide
40 of Table V.
e Not hydrolyzed when incubated with 140 nM HIV-1 proteinase for
1 h at 37 °C.
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of the specificity (35) might give better results. Also, molecular
modeling and improved energy calculation methods may help
to develop better methods for predictions.
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